Goyo,

I'll have to listen to that again but if that's what he said it would certainly be contrary to what he said less than a month ago...

"Patients recruitment for both Phase III trials was completed in early October. The addition of sites and the existing geographic areas, the initiation of high-rolling sites in Brazil and the continuation of the patient profile program for the U.S. sites were critical to achieving this milestone.

We are now concentrating our execution of these trials and in maintaining the high level of monitoring necessary to ensure well-defined data set. The last patient last visit for the 175 study will take place in May of 2013, and the last patient last visit for the 171 study will follow shortly thereafter. We are currently developing a detailed operational plan for the rapid database look and the production of final tables, figures and listings. We expect to share the key trial results with you prior to submission. Submission is planned for the third quarter, and we expect that the resubmission will undergo a 6-month review. All the activities to support the resubmission are well under way, and none of them represent a rate limiting challenge."

http://seekingalpha.com/article/971551-mannkind-management-discusses-q3-2012-results-earnings-call-transcript?find=enroll&all=false